Milrinone During Living Donor Hepatectomy

This study has been completed.
Sponsor:
Information provided by:
Seoul National University Hospital
ClinicalTrials.gov Identifier:
NCT00966745
First received: August 13, 2009
Last updated: August 26, 2009
Last verified: August 2009
  Purpose

Maintaining a low central venous pressure during living donor hepatectomy is routine practice. The investigators tried to test the hypothesis that using milrinone to maintain a low central venous pressure (CVP) during is associated with a superior surgical field and less blood loss.


Condition Intervention
Hepatectomy
Drug: milrinone
Drug: placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Effect of Milrinone During Living Donor Hepatectomy Using a Low Central Venous Pressure Technique

Resource links provided by NLM:


Further study details as provided by Seoul National University Hospital:

Primary Outcome Measures:
  • condition of surgical field [ Time Frame: intraoperative period (from the start of surgery to end of living donor hepatectomy) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • the use of vasopressor and diuretics to maintain hemodynamic stability and low CVP status, respectively [ Time Frame: intraoperative period (from the start of surgery to end of living donor hepatectomy) ] [ Designated as safety issue: No ]

Enrollment: 38
Study Start Date: January 2008
Study Completion Date: December 2008
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: milrinone
milrinone infusion
Drug: milrinone
Placebo Comparator: placebo Drug: placebo

  Eligibility

Ages Eligible for Study:   19 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Living liver donors

Exclusion Criteria:

  • Donors with concurrent cardiac, pulmonary, and urologic disease
  • Hepatectomy performed laparoscopically
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00966745

Locations
Korea, Republic of
Seoul National University Hospital
Seoul, Korea, Republic of, 110-744
Sponsors and Collaborators
Seoul National University Hospital
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00966745     History of Changes
Other Study ID Numbers: mil_living_liver_donor
Study First Received: August 13, 2009
Last Updated: August 26, 2009
Health Authority: Korea: Food and Drug Administration
Korea: Ministry for Health, Welfare and Family Affairs

Keywords provided by Seoul National University Hospital:
surgical field condition

Additional relevant MeSH terms:
Milrinone
Platelet Aggregation Inhibitors
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions
Vasodilator Agents
Cardiovascular Agents
Phosphodiesterase 3 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cardiotonic Agents
Protective Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on April 17, 2014